SynthesisTherapeutic delivery2025
Are hydrogels suitable for delivery of cisplatin to the microenvironment in breast cancer treatment: a meta-analysis.
Synthesis in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the most commonly diagnosed cancer for women. Cisplatin is one the most potent chemotherapeutic drugs we know in breast cancer, but its systemic toxicity limits its clinical application. Hydrogels are a local drug delivery system that limits the systemic toxicity of drugs and improves their efficacy.
objectivesThis systematic review and meta-analysis evaluated the preclinical efficacy of cisplatin-loaded hydrogels for breast cancer treatment.
methodsWe had a systematic search on different databases, including PubMed, Scopus, MEDLINE, Embase, Google Scholar, and the Web of Science, to find relative papers.
resultsThere was no statistically significant difference in cell viability between the cisplatin-loaded hydrogel and free cisplatin groups. However, the IC50 values were significantly higher in the treatment group, which means the cytotoxicity was reduced in the cisplatin-loaded hydrogel; then, we subgrouped them based on cell line and treatment duration; no significant difference was observed between the subgroups.
conclusionsThis meta-analysis evaluated cisplatin-loaded hydrogels versus free cisplatin in breast cancer treatment. Contrary to expectations, no significant difference in cell viability was found, indicating hydrogels did not enhance therapeutic efficacy. However, a significantly higher IC50 with hydrogels suggests reduced instantaneous drug concentration due to sustained release. PROSPERO: CRD42025641451.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.